Ireland
--:--IST
Recruiting Observational

Urine Metabolites in the Diagnosis of Disease

NCT06710067 · tracked via the Priya Life Science USA tracker
Sponsor
Luventix, Inc
Phase
Observational
Started
2024-10-01
Last updated
2024-12-13

Condition(s) studied

Colorectal CancerSmall Intestinal Bacterial Overgrowth Syndrome (SIBO)Crohn DiseaseCeliac Disease

Study summary

The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.

This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.

The main questions it aims to answer are:

1. Does the platform identify a disease signal within each disease cohort, compared to normal controls?
2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 18 years of age at time of enrollment. * Able and willing to provide a one-time urine sample and comply with all study procedures for the study. * Able to understand the study procedures, able to provide consent to participate in the study, and willing to authorize release of relevant protected health information by consenting to a HIPAA medical release form. Exclusion Criteria: * Known to be pregnant. * A medical condition which, in the opinion of the Investigator and/or Sponsor, should preclude enrollment in the study.

Primary outcome measure(s)

  • Disease signal detection — From date of enrollment to the end of sample analysis, up to 100 weeks
    Disease signal detection quantification within each disease cohort, compared to normal controls.
  • Test performance measures — From date of enrollment to the end of sample analysis, up to 100 weeks
    Sensitivity and specificity/false-positive rate

Trial sites (4)

FacilityCityRegionStatus
Unio Health Partners (Gastroenterology) Encinitas California Recruiting
Digestive Health Associates Santa Monica California Recruiting
Westside Gastro Care Santa Monica California Recruiting
Bass Medical Group (Gastroenterology) Walnut Creek California Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06710067 on ClinicalTrials.gov ↗ ← All trials in the USA